Tenpoint Therapeutics has submitted a Marketing Authorization Application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency for YUVEZZI, its once-daily prescription eye drop for adults with presbyopia. The filing seeks permission to market the dual-agent therapy, which combines carbachol and brimonidine tartrate at concentrations of 2.75% and 0.1%, respectively. The submission represents a major step in the company’s strategy to expand the product beyond the United States following its FDA approval in January 2026.
Streamlined UK Regulatory Route
The application was filed through the MHRA’s International Recognition Procedure, a pathway that allows the UK regulator to consider assessments and approvals issued by recognized overseas authorities. In YUVEZZI’s case, the MHRA can take the FDA’s decision into account while conducting its own targeted review of the medicine’s quality, safety, and effectiveness. The process is intended to reduce unnecessary duplication and potentially shorten review timelines, although the MHRA retains full authority to request additional evidence or reject an application.
A New Approach to Presbyopia
Presbyopia is an age-related decline in near vision that commonly begins around age 45 and can make routine activities such as reading, texting, and checking labels increasingly difficult. Traditional management options include reading glasses, contact lenses, and surgical procedures, while prescription eye drops have emerged as another potential treatment category. YUVEZZI is designed to improve close-up vision by constricting the pupil and creating a pinhole effect that increases depth of focus without relying on corrective lenses.
Phase 3 Evidence Supporting the Filing
Tenpoint’s UK application is supported by results from the randomized, double-masked BRIO I and BRIO II Phase 3 studies, which evaluated the combination treatment against its individual components or a vehicle control. According to the company, a single daily dose produced statistically significant improvements in near vision, while pupil constriction was observed from 30 minutes after administration and continued for as long as 10 hours. The broader clinical program involved more than 800 participants, with no treatment-related serious adverse events reported across up to 12 months and more than 72,000 dosing days.
US Approval and Commercial Validation
The FDA approved YUVEZZI on January 28, 2026, for the treatment of presbyopia in adults, making it the first approved fixed-dose eye drop combining carbachol and brimonidine tartrate for this indication. The US decision followed evidence that the combination delivered greater pupil reduction than either active ingredient alone and improved binocular near visual acuity without a clinically significant loss of distance vision. The approval provided Tenpoint with an important regulatory reference for pursuing authorization in the UK and other international markets.
Global Expansion Opportunity
Tenpoint estimates that presbyopia affects about two billion people worldwide, including as many as 30 million individuals in the UK, creating a substantial potential market for convenient nonsurgical treatments. A UK authorization would give eye-care professionals and patients another option for managing near-vision loss while supporting the company’s transition into a broader commercial ophthalmology business. Tenpoint has also indicated that it plans to submit additional regulatory applications in other major regions as part of its international expansion program.
The MHRA submission moves YUVEZZI closer to possible commercialization in the UK and tests whether Tenpoint can translate its US regulatory success into a wider global presence. Although submission does not guarantee approval, use of the International Recognition Procedure may allow the regulator to build on the FDA’s prior evaluation while independently assessing the product for UK patients. A positive decision would expand the emerging market for prescription presbyopia drops and strengthen Tenpoint’s position in treatments targeting age-related vision changes.